Shoals Technologies Group (SHLS) shares fell roughly 17% over the last 30 days, declining from about $9.62 to $7.95. Second-quarter 2026 results beat Wall Street estimates on revenue and earnings, but unchanged full-year guidance and margin pressure dampened investor sentiment.

AXT shares climbed roughly 50% over the last 30 days, from a closing price of $48.83 on July 20 to $73.43 on August 19, 2026. The rally was driven primarily by record second-quarter results reported on July 30, including revenue up 164% year over year and a return to profitability.

AXT, Inc. ( AXTI ) closed near $73, making a return to the $100 level a gain of roughly 35% from current prices. The strongest bull case rests on record demand for indium phosphide (InP) substrates used in AI data center optical transceivers.

PLTR climbed roughly 32% over the past 30 days, from a close of $132.66 on July 21, 2026 to $175.19 on Aug. 19, 2026. The surge was driven primarily by a record second-quarter earnings report, released after the market closed on Aug. 3, 2026.

The central question is whether Palantir Technologies Inc. (PLTR) can reach a $300 stock price target , roughly 70% above its recent trading level near $175. The strongest bullish case rests on exceptional revenue growth, an expanding AI-driven contract pipeline, and a record remaining deal value that supports future revenue.

Omeros Corporation (OMER) shares climbed roughly 91% over the trailing 30-day period, rising from about $9.63 to $18.39 as the company's commercial launch gained momentum. The primary catalyst was second-quarter 2026 results showing a swing to profitability, driven by a 190% sequential jump in YARTEMLEA revenue.

The stock price target in focus is $50 , a psychological round-number milestone roughly 30% above the latest closing level near $38.60. The strongest bullish factor is positive Phase 3 LUCIDITY data for the lead drug candidate, avexitide, which triggered a wave of analyst price-target increases as high as $55.

AMLX shares surged roughly +108.6% over the past 30 days, climbing from $18.50 to a recent close of $38.60, driven primarily by positive Phase 3 LUCIDITY trial results. The pivotal data for avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH), met its primary endpoint and all secondary endpoints with a clean safety profile.

WDAY has climbed roughly 34.7% over the trailing 30 days, rising from about $147.22 on July 20 to approximately $198.34 in recent trading. The sharpest single move came on August 13, when a Reuters report that Silver Lake has held talks to take Workday private sent shares up nearly 18% — their best one-day gain since 2016.

Copart (CPRT) shares climbed roughly 23% over the last 30 days, rising from about $27.49 to around $33.86 in intraday trading on August 19, 2026. The advance was fueled by founder Jay Adair's return as CEO, a renewed focus on deploying roughly $4.2 billion of cash toward acquisitions, and reports that Copart is among the suitors for car-insurance software provider CCCS .

Gold Fields (GFI) has climbed roughly 40% over the last 30 days, rising from a closing price near $31.25 to about $43.86, according to recent market data. The rally has been driven by a strong gold-price environment and a sharply improved first-half 2026 trading statement showing headline earnings up 72% to 90% year over year.

AngloGold Ashanti (AU) rose roughly 45% over the last 30 days, from about $74.88 to above $108 per share, driven by surging gold prices and a strong second-quarter earnings report. The company reported sharply higher profitability in Q2 2026, including EBITDA up 46% to $2 billion and a $2 billion share repurchase program, reinforcing investor confidence.

Investors are asking whether Cardiol Therapeutics (CRDL) can climb to the $5 level, a round psychological milestone and the low end of Wall Street's published price-target range. With shares recently trading near $1.90, reaching $5 would require roughly a 160% advance from current levels.

The $5 price target is not arbitrary — it matches the current street-high bull case, with H.C. Wainwright maintaining a $5 objective and BTIG carrying a $6 target. Reaching $5 from roughly $2.20 would require a gain of well over 100%, far above the consensus analyst price target of about $3.10.

MRK surged +13.04% to $152.80 on Wednesday, with gains beginning in premarket and accelerating during the regular session. The catalyst: Merck and Moderna announced positive Phase 3 INTerpath-001 results, the first late-stage win for an mRNA cancer vaccine.

The central question is whether SoFi Technologies (SOFI) can climb back to the $30 level, roughly 65% above its recent trading range near $18. The strongest bullish factors are a national bank charter, accelerating member and product growth, and a rapidly expanding fee-based revenue mix.

FEIM fell -8.65% to about $68.67 from a prior close of $75.17, declining during regular market hours on Wednesday. The drop followed Q4 fiscal 2026 results reported after the close on Aug. 18, with revenue of $15.4M missing the $18.6M consensus estimate.

EMAT fell -8.97% to $2.84 during the regular session, giving back most of the prior day's +11.83% rebound. The decline reflects profit-taking and fading "buy-the-dip" momentum after a sharp technical bounce off 52-week lows.

CENX fell -8.37% to $41.84 during regular trading hours, extending a pullback from its prior-session close of $45.66. The slide reflects profit-taking after a sharp rally, with traders locking in gains amid a broad unwind of the stock's hot momentum.

VICR fell -12.26% during regular trading, sliding to roughly $212.69 from a prior close of $242.41. The drop came despite strong Q2 results (EPS $1.04 vs. $0.65 estimate; revenue +49.3% YoY), signaling a "sell the news" profit-taking move.